Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management

1. Bischof JJ, Presley CJ, Caterino JM. Addressing new diagnostic and treatment challenges associated with a new age of cancer treatment. Ann Emerg Med 2019; 73: 88–90. doi: 10.1016/j.annemergmed.2018.08.421 BischofJJ PresleyCJ CaterinoJM Addressing new diagnostic and treatment challenges associated with a new age of cancer treatment Ann Emerg Med 2019 73 88 90 10.1016/j.annemergmed.2018.08.421 Open DOISearch in Google Scholar

2. Mayer DK, Travers D, Wyss A, Leak A, Waller A. Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol 2011; 29: 2683–8. doi: 10.1200/JCO.2010.34.2816 MayerDK TraversD WyssA LeakA WallerA Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina J Clin Oncol 2011 29 2683 8 10.1200/JCO.2010.34.2816 Open DOISearch in Google Scholar

3. Lewis MA, Hendrickson WA, Moynihan TJ. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 2011; 61: 287–314. doi: 10.3322/caac.20124 LewisMA HendricksonWA MoynihanTJ Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment CA Cancer J Clin 2011 61 287 314 10.3322/caac.20124 Open DOISearch in Google Scholar

4. Alahmadi A, Altamimi H, Algarni M. Evaluation of knowledge of immunotherapy toxicities among emergency physicians in Riyadh, Saudi Arabia. Cureus 2022; 14: e30325. doi: 10.7759/cureus.30325 AlahmadiA AltamimiH AlgarniM Evaluation of knowledge of immunotherapy toxicities among emergency physicians in Riyadh, Saudi Arabia Cureus 2022 14 e30325 10.7759/cureus.30325 Open DOISearch in Google Scholar

5. Higdon ML, Higdon JA. Treatment of oncologic emergencies. Am Fam Physician 2006; 74: 1873–80. PMID: 17168344 HigdonML HigdonJA Treatment of oncologic emergencies Am Fam Physician 2006 74 1873 80 17168344 Search in Google Scholar

6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–64. doi: 10.1038/nrc3239 PardollDM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 252 64 10.1038/nrc3239 Open DOISearch in Google Scholar

7. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559–74. doi: 10.1093/annonc/mdv623 ChampiatS LambotteO BarreauE BelkhirR BerdelouA CarbonnelF Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper Ann Oncol 2016 27 559 74 10.1093/annonc/mdv623 Open DOISearch in Google Scholar

8. Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 2020; 9: e013757. doi: 10.1161/JAHA.119.013757 PalaskasN Lopez-MatteiJ DurandJB Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment J Am Heart Assoc 2020 9 e013757 10.1161/JAHA.119.013757 Open DOISearch in Google Scholar

9. Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Matthias Endres M, et al. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer 2022; 175: 224–35. doi: 10.1016/j.ejca.2022.08.009 Müller-JensenL ZieroldS VersluisJM BoehmerleW HuehnchenP Matthias EndresM Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study Eur J Cancer 2022 175 224 35 10.1016/j.ejca.2022.08.009 Open DOISearch in Google Scholar

10. Haanen J, Obeid N, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217–38. doi: 10.1016/j.annonc.2022.10.001 HaanenJ ObeidN SpainL CarbonnelF WangY RobertC Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2022 33 1217 38 10.1016/j.annonc.2022.10.001 Open DOISearch in Google Scholar

11. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267–76. doi: 10.1038/nrclinonc.2013.46 KochenderferJN RosenbergSA Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors Nat Rev Clin Oncol 2013 10 267 76 10.1038/nrclinonc.2013.46 Open DOISearch in Google Scholar

12. Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021; 18: 71–84. doi: 10.1038/s41571-020-0427-6 MikkilineniL KochenderferJN CAR T cell therapies for patients with multiple myeloma Nat Rev Clin Oncol 2021 18 71 84 10.1038/s41571-020-0427-6 Open DOISearch in Google Scholar

13. Kish J, Liu R, Pfeffer D, Vennam S, Lussier C, Nayak P. Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies. [abstract]. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). J Clin Oncol 2023; 41(Suppl S): e18896. doi: Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol 2020; 17: 418–34. doi: 10.1038/s41571-020-0347-5 KishJ LiuR PfefferD VennamS LussierC NayakP Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies. [abstract]. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) J Clin Oncol 2023 41 Suppl S e18896 doi: Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol 2020; 17: 418–34. 10.1038/s41571-020-0347-5 Open DOISearch in Google Scholar

14. Ball K, Dovedi SJ, Vajjah P, Phipps A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. mAbs 2023; 15: 2181016. doi: 10.1080/19420862.2023.2181016 BallK DovediSJ VajjahP PhippsA Strategies for clinical dose optimization of T cell-engaging therapies in oncology mAbs 2023 15 2181016 10.1080/19420862.2023.2181016 Open DOISearch in Google Scholar

15. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383: 2255–73. doi: 10.1056/NEJMra2026131 FajgenbaumDC JuneCH Cytokine storm N Engl J Med 2020 383 2255 73 10.1056/NEJMra2026131 Open DOISearch in Google Scholar

16. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625–38. doi: 10.1016/j.bbmt.2018.12.758 LeeDW SantomassoBD LockeFL GhobadiA TurtleCJ BrudnoJN ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells Biol Blood Marrow Transplant 2019 25 625 38 10.1016/j.bbmt.2018.12.758 Open DOISearch in Google Scholar

17. Hernani R, Benzaquén A, Solan C. Toxicities following CAR-T therapy for hematological malignancies. Cancer Treat Rev 2022: 111: 102479. doi: 10.1016/j.ctrv.2022.102479 HernaniR BenzaquénA SolanC Toxicities following CAR-T therapy for hematological malignancies Cancer Treat Rev 2022 111 102479 10.1016/j.ctrv.2022.102479 Open DOISearch in Google Scholar

18. Morris EM, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022; 22: 85–96. doi: 10.1038/s41577-021-00547-6 MorrisEM NeelapuSS GiavridisT SadelainM Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy Nat Rev Immunol 2022 22 85 96 10.1038/s41577-021-00547-6 Open DOISearch in Google Scholar

19. Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program 2023; 2023: 198–208. doi: 10.1182/hematology.2023000472 RejeskiK SubkleweM LockeFL Recognizing, defining, and managing CAR-T hematologic toxicities Hematology Am Soc Hematol Educ Program 2023 2023 198 208 10.1182/hematology.2023000472 Open DOISearch in Google Scholar

20. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018; 15: 47–62. doi: 10.1038/nrclinonc.2017.148. NeelapuSS TummalaS KebriaeiP WierdaW GutierrezC LockeFL Chimeric antigen receptor T-cell therapy - assessment and management of toxicities Nat Rev Clin Oncol 2018 15 47 62 10.1038/nrclinonc.2017.148 Open DOISearch in Google Scholar

21. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO Guideline. J Clin Oncol 2021; 39: 3978–92. doi: 10.1200/JCO.21.01992 SantomassoBD NastoupilLJ AdkinsS LacchettiC SchneiderBJ AnadkatM Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO Guideline J Clin Oncol 2021 39 3978 92 10.1200/JCO.21.01992 Open DOISearch in Google Scholar

22. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 2020; 4: 3123–7. doi: 10.1182/bloodadvances.2020002328 StratiP AhmedS KebriaeiP NastoupilLJ ClaussenCM WatsonG Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma Blood Adv 2020 4 3123 7 10.1182/bloodadvances.2020002328 Open DOISearch in Google Scholar

23. Rosée PL, Horne AC, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133: 2465–77. doi: 10.1182/blood.2018894618 RoséePL HorneAC HinesM von Bahr GreenwoodT MachowiczR BerlinerN Recommendations for the management of hemophagocytic lymphohistiocytosis in adults Blood 2019 133 2465 77 10.1182/blood.2018894618 Open DOISearch in Google Scholar

24. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 2021; 18: 327–44. doi: 10.1038/s41571-021-00470-8 DragoJZ ModiS ChandarlapatyS Unlocking the potential of antibody-drug conjugates for cancer therapy Nat Rev Clin Oncol 2021 18 327 44 10.1038/s41571-021-00470-8 Open DOISearch in Google Scholar

25. Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 2024; 21: 203–23. doi: 10.1038/s41571-023-00850-2 TsuchikamaK AnamiY HaSYY YamazakiCM Exploring the next generation of antibody-drug conjugates Nat Rev Clin Oncol 2024 21 203 23 10.1038/s41571-023-00850-2 Open DOISearch in Google Scholar

26. Tarantino P, Ricciuti B, Pradhan SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 2023; 20: 558–76. doi: 10.1038/s41571-023-00783-w TarantinoP RicciutiB PradhanSM Optimizing the safety of antibody-drug conjugates for patients with solid tumours Nat Rev Clin Oncol 2023 20 558 76 10.1038/s41571-023-00783-w Open DOISearch in Google Scholar

27. Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract 2023; 19: 539–46. doi: 10.1200/OP.22.00480 RugoHS CrossnoCL GesthalterYB KelleyK MooreHB RimawiMF Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer JCO Oncol Pract 2023 19 539 46 10.1200/OP.22.00480 Open DOISearch in Google Scholar

28. Lacouture ME, Patel AB, Rosenberg JE, Peter H O’Donnell. Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 2022; 27: e223–32. doi: 10.1093/oncolo/oyac001 LacoutureME PatelAB RosenbergJE PeterH O’Donnell Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin Oncologist 2022 27 e223 32 10.1093/oncolo/oyac001 Open DOISearch in Google Scholar

29. Cooksley T, Rice T. Emergency oncology: development, current position and future direction in the USA and UK. Support Care Cancer 2017; 25: 3–7. doi: 10.1007/s00520-016-3470-1 CooksleyT RiceT Emergency oncology: development, current position and future direction in the USA and UK Support Care Cancer 2017 25 3 7 10.1007/s00520-016-3470-1 Open DOISearch in Google Scholar